

**Amendments to the Specification:**

Please amend the paragraph at page 1, line 4 as follows.

This application is a continuation of U.S. Serial No. 09/726,774, filed November 29, 2000, which claims priority to U.S. Provisional Application No. 60/168,150, filed November 29, 1999, each of which is incorporated in its entirety herein by reference.

Please amend the paragraph at page 6, line 12 as follows.

In a related aspect ~~aspseet~~, the invention provides a method of treating a bacterial infection in a human or mammalian animal subject, by administering to the subject, in a pharmaceutically effective amount, a substantially uncharged antisense oligomer as described above. Various selected embodiments of the oligomer and the target sequence are as described above. Preferably, the antisense oligomer is administered in an amount and manner effective to result in a peak blood concentration of at least 200-400 nM antisense oligomer. The method can be used, for example, for treating bacterial infections of the skin, wherein administration is by a topical route, or for use in treating a bacterial respiratory infection, wherein administration is by inhalation.

After page 46, please insert the Sequence Listing on pages 1-33, enclosed herewith.